Intra-Cellular Therapies announced positive results from a Phase 3 clinical trial for its antipsychotic medicine Caplyta in treating major depressive disorder. The study showed a significant reduction in depressive symptoms compared to a placebo on the MADRS scale. The drug also demonstrated benefits on a patient-reported measure of depression severity. Common side effects included dry mouth, fatigue, and tremor, but overall tolerability was consistent with previous studies. These findings indicate the potential for Caplyta to be used for treating major depressive disorder in addition to its current indication for schizophrenia.
Source link
Intra-Cellular reports positive results in depression study
